-+ 0.00%
-+ 0.00%
-+ 0.00%

Exsitec Holding (OM:EXS) Q3 Earnings Reveal Acquisition Strain And Margin Strength

Simply Wall St·10/20/2026 23:31:39
Listen to the news

Exsitec Holding entered today’s Q3 2026 report with the share price at SEK110.5, roughly flat over the past week and modestly weaker over the past month. On the surface, the headline that stands out is the swing from Q2 profit to a Q3 loss of SEK 13.3m, driven by heavy restructuring tied to the Amesto acquisition. Short-term traders may focus on the negative earnings figure and move on. Long horizon holders are more likely watching the 12.9% adjusted EBITA margin and recurring software revenue trend as the main points of interest.

Like the Exsitec Holding margin profile but uncomfortable with a fresh quarterly loss tied to restructuring costs? The screener for sturdier setups with profit resilience is a good next benchmark, starting with the list of solid balance sheet and fundamentals stocks (202 results).

Q3 2026 Earnings Summary

  • Revenue (Q3 2026 vs. Q3 2025): SEK 231.9m vs. SEK 187.6m (up about 24%)
  • Net Income/Loss (Q3 2026 vs. Q3 2025): loss of SEK 13.3m vs. profit of SEK 9.9m (swing into loss, mainly restructuring related)
  • Basic EPS (Q3 2026 vs. Q3 2025): loss of SEK 0.99 per share vs. profit of SEK 0.74 per share (earnings moved into loss)
  • Adjusted EBITA Margin (Q3 2026 vs. Q3 2025): 12.9%. Company commentary highlighted a lower margin level a year earlier, and the reported margin shows improvement on an adjusted basis.

Tired of wrestling with dense reports and scattered earnings snippets? Get a clear, visual snapshot of Exsitec Holding that brings its valuation picture into focus through the full company report for Exsitec Holding.

OM:EXS Trailing 12-Month Earnings & Revenue History as at Oct 2026
OM:EXS Trailing 12-Month Earnings & Revenue History as at Oct 2026

Exsitec bullish story on recurring software under review

"Expansion of Exsitec Holding's higher margin recurring software stream, which reached SEK 246 million over the last twelve months and now accounts for about 26% of year to date revenue, could gradually lift earnings quality and support more resilient net margins if this mix shift continues."

Exsitec Holding is at least moving in the direction this claim describes. Recurring software revenue LTM sits at SEK 270m, with 24% growth and 14% organic growth. That mix helps explain why adjusted EBITA margin holds at 12.9% despite softer consulting activity and Amesto related disruption. The problem is the reported Q3 loss. One off restructuring of about SEK 27m means the promised resilience is not yet visible in statutory profit.

Bear case on M&A strain and organic growth tested

"The increased focus on integrating acquired companies and the ongoing use of M&A, including large deals such as Amesto Solutions, could still lead to higher integration costs, slower realization of synergies or operational inefficiencies, which would pressure net margins and earnings if the integrations do not go as planned."

The Q3 print gives this concern real weight. Restructuring tied to Amesto, roughly SEK 27m, flips Exsitec Holding into a quarterly loss and shows integration costs arriving faster than synergy benefits. Management now flags SEK 35m annual savings from Q1 2027, so the economic logic looks intact. For now, higher reported expenses and only modest organic growth of 3% show that consolidation is helping scale but still straining the income statement.

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for.

Hunt For Mispriced Earnings Power

Exsitec Holding reports a quarter with moving parts that headline profit and loss figures do not fully explain. The real opportunity is searching for stocks that could be undervalued before the market reassesses their earnings power.

  • Company 1 - 40% below our estimate - uses heavier spend on AI, branches and payments to pursue fee income and operating leverage.
  • Company 2 - 25% below our estimate - designs liquid cooling systems for data centres as GPU power density strains traditional air and water setups.
  • Company 3 - 22% below our estimate - builds elastomer components and capsules that gain importance as high-margin healthcare and GLP-1 treatment volumes expand.

That is three of the list. See every one of the 189 undervalued companies on it →